Evaluation of silver nanoparticles for the prevention of SARS-CoV-2 infection in health workers: In vitro and in vivo
Open accessPublished version of a preprint
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
SARS-CoV-2 infection in hospital areas is of a particular concern, since the close interaction between health care personnel and patients diagnosed with COVID-19, which allows virus to be easily spread between them and subsequently to their families and communities. Preventing SARS-CoV-2 infection among healthcare personnel is essential to reduce the frequency of infections and outbreaks during the pandemic considering that they work in high-risk areas. In this research, silver nanoparticles (AgNPs) were tested in vitro and shown to have an inhibitory effect on SARS-CoV-2 infection in cultured cells. Subsequently, we assess the effects of mouthwash and nose rinse with ARGOVIT ® silver nanoparticles (AgNPs), in the prevention of SARS-CoV-2 contagion in health workers consider as high-risk group of acquiring the infection in the General Tijuana Hospital, Mexico, a hospital for the exclusive recruitment of patients diagnosed with COVID-19. We present a prospective randomized study of 231 participants that was carried out for 9 weeks (during the declaration of a pandemic). The "experimental" group was instructed to do mouthwash and nose rinse with the AgNPs solution; the "control" group was instructed to do mouthwashes and nose rinse in a conventional way. The incidence of SARS-CoV-2 infection was significantly lower in the "experimental" group (two participants of 114, 1.8%) compared to the "control" group (thirty-three participants of 117, 28.2%), with an 84.8% efficiency. We conclude that the mouth and nasal rinse with AgNPs helps in the prevention of SARS-CoV-2 infection in health personnel who are exposed to patients diagnosed with COVID-19.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both studies reported large protective effects of the intervention on SARS‐CoV‐2 infection with reported outcomes of SARS‐C0V‐2 infection in 28.2% and 12.7% in the HCWs not using the interventions versus 1.8% and 1.2% in those using the intervention”
From Physical interventions to interrupt or reduce the spread of respiratory viruses (2023) · cites this paper as Almanza-Reyes 2021
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“One study provided insufficient information to enable judgment (Almanza‐Reyes 2021).”
From Physical interventions to interrupt or reduce the spread of respiratory viruses (2023) · cites this paper as Almanza-Reyes 2021
The cited source says what the claim attributes to it.
In the citing paper
“There were no adverse reactions in the study by Almanza‐Reyes 2021 or side effects in the study by Gutiérrez‐García 2022.”
From Physical interventions to interrupt or reduce the spread of respiratory viruses (2023) · cites this paper as Almanza‐Reyes 2021
The cited source says what the claim attributes to it.
In the citing paper
“Almanza‐Reyes 2021 reported the incidence of SARS‐CoV‐2 infection was statistically significantly lower in the silver mouth wash/nose rinse group (two out of 114, 1.8%) compared to the conventional mouthwash group (33 out of 117, 28.2%)”
From Physical interventions to interrupt or reduce the spread of respiratory viruses (2023) · cites this paper as Almanza‐Reyes 2021
The cited source says what the claim attributes to it.
In the citing paper
“Two trials of mouthwash/nose rinse were conducted during the SARS‐cov‐2 pandemic in HCWs: Almanza‐Reyes 2021 compared silver mouth wash/nose rinse versus conventional mouthwashes and nose rinse; and Gutiérrez‐García 2022 compared neutral electrolysed water mouth and nose rinses versus no rinses.”
From Physical interventions to interrupt or reduce the spread of respiratory viruses (2023) · cites this paper as Almanza-Reyes 2021
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia
Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. M. E., & Fouchier, R. A. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1211721 · Cited by 5,735 · cited 1×
“On the other hand, no vaccine has been created so far against any coronavirus causing the last three pandemics such as SARS-CoV in 2002 [16], MERS-CoV in 2012 [17] and SARS-CoV-2 in 2019 [18].”
BackgroundAn mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Transmission routes of 2019-nCoV and controls in dental practice
Peng, X., Xu, X., Li, Y., Cheng, L., Zhou, X., & Ren, B. (2020) · International Journal of Oral Science · doi:10.1038/s41368-020-0075-9 · Cited by 2,437 · cited 3×
“These results justify making changes to the international recommendations [33] on new dental clinical practices and the prevention of SARS-CoV-2.”
BackgroundResultInfluentialFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
Guan, Y., Zheng, B. J., He, Y. Q., Liu, X. L., Zhuang, Z. X., Cheung, C. L., Luo, S. W., Li, P. H., Zhang, L. J., Guan, Y. J., et al. (2003) · Science · doi:10.1126/science.1087139 · Cited by 2,406
Consistent Detection of 2019 Novel Coronavirus in Saliva
To, K. K.-W., Tsang, O. T.-Y., Yip, C. C.-Y., Chan, K.-H., Wu, T.-C., Chan, J. M.-C., Leung, W.-S., Chik, T. S.-H., Choi, C. Y.-C., Kandamby, D. H., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa149 · Cited by 1,873 · cited 1×
“2 × 10(8) infectious copies / per mL [32].”
BackgroundLogunov, D. Y., Dolzhikova, I. V., Shcheblyakov, D. V., Tukhvatulin, A. I., Zubkova, O. V., Dzharullaeva, A. S., Kovyrshina, A. V., Lubenets, N. L., Grousova, D. M., Erokhova, A. S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00234-8 · Cited by 1,747
Multiple organ infection and the pathogenesis of SARS
Gu, J., Gong, E., Zhang, B., Zheng, J., Gao, Z., Zhong, Y., Zou, W., Zhan, J., Wang, S., Xie, Z., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050828 · Cited by 1,379
Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study.
Ren, L.-L., Wang, Y.-M., Wu, Z.-Q., Xiang, Z.-C., Guo, L., Xu, T., Jiang, Y.-Z., Xiong, Y., Li, Y.-J., Li, X.-W., et al. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000722 · Cited by 1,349 · cited 1×
“On the other hand, no vaccine has been created so far against any coronavirus causing the last three pandemics such as SARS-CoV in 2002 [16], MERS-CoV in 2012 [17] and SARS-CoV-2 in 2019 [18].”
BackgroundZhu, F.-C., Guan, X.-H., Li, Y.-H., Huang, J.-Y., Jiang, T., Hou, L.-H., Li, J.-X., Yang, B.-F., Wang, L., Wang, W.-J., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31605-6 · Cited by 1,225
Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
Keech, C., Albert, G., Cho, I., Robertson, A., Reed, P., Neal, S., Plested, J. S., Zhu, M., Cloney-Clark, S., Zhou, H., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2026920 · Cited by 1,156
Randhawa, G. S., Soltysiak, M. P. M., El Roz, H., de Souza, C. P. E., Hill, K. A., & Kari, L. (2020) · PLOS ONE · doi:10.1371/journal.pone.0232391 · Cited by 1,023
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs
Jeon, S., Ko, M., Lee, J., Choi, I., Byun, S. Y., Park, S., Shum, D., & Kim, S. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00819-20 · Cited by 675 · cited 1×
“Different candidate drugs have been identified as antivirals against SARS-CoV-2 [9], but there are only very few drugs approved by the US Food and Drug Administration (FDA||) [10].”
BackgroundSalleh, A., Naomi, R., Utami, N. D., Mohammad, A. W., Mahmoudi, E., Mustafa, N., & Fauzi, M. B. (2020) · Nanomaterials · doi:10.3390/nano10081566 · Cited by 581 · cited 1×
“The mechanism by which AgNPs interact with viruses is not yet clear, but it has been proposed that AgNPs, as well as other metallic nanoparticles, interfere with the structural proteins of the virus by inhibiting their ability to bind with cell receptors or bind to genetic material of viruses by inhibiting their repli…”
BackgroundPotent antiviral effect of silver nanoparticles on SARS-CoV-2
Jeremiah, S. S., Miyakawa, K., Morita, T., Yamaoka, Y., & Ryo, A. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.09.018 · Cited by 431 · cited 1×
“Since the nanoparticles used in these experiments are mixed with hydrolyzed collagen, a compound that stabilizes nanoparticles and reduces its toxicity in cell culture [26], we were able to assess higher concentrations than those used in other articles.”
ResultSchwartz, J., King, C.-C., & Yen, M.-Y. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa255 · Cited by 415 · cited 1×
“9) in the control group, the experimental group had the lowest number of COVID-19 infections, being the group that washed their hands less frequently, this indicates that AgNPs contributed to mitigating the SARS-CoV-2 infection in the experimental group, consistent handwashing has previously been recognized as a prote…”
BackgroundButowt, R., & Bilinska, K. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00172 · Cited by 346
Jaume, M., Yip, M. S., Cheung, C. Y., Leung, H. L., Li, P. H., Kien, F., Dutry, I., Callendret, B., Escriou, N., Altmeyer, R., et al. (2011) · Journal of Virology · doi:10.1128/jvi.00671-11 · Cited by 314
Work-related COVID-19 transmission in six Asian countries/areas: A follow-up study
Lan, F.-Y., Wei, C.-F., Hsu, Y.-T., Christiani, D. C., & Kales, S. N. (2020) · PLOS ONE · doi:10.1371/journal.pone.0233588 · Cited by 270 · cited 1×
“Caring for SARS-CoV-2 patients is a high risk exposition and causes complications due to the high mortality and morbidity [4].”
BackgroundWong, S. C. Y., Kwong, R. T.-S., Wu, T. C., Chan, J. W. M., Chu, M. Y., Lee, S. Y., Wong, H. Y., & Lung, D. C. (2020) · Journal of Hospital Infection · doi:10.1016/j.jhin.2020.03.036 · Cited by 241 · cited 1×
“In turn, there is a risk of nosocomial infections among patients with COVID-19 and patients without a diagnosis of atypical pneumonia [5].”
BackgroundAntiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets
Park, S.-J., Yu, K.-M., Kim, Y.-I., Kim, S.-M., Kim, E.-H., Kim, S.-G., Kim, E. J., Casel, M. A. B., Rollon, R., Jang, S.-G., et al. (2020) · mBio · doi:10.1128/mbio.01114-20 · Cited by 185 · cited 1×
“Different candidate drugs have been identified as antivirals against SARS-CoV-2 [9], but there are only very few drugs approved by the US Food and Drug Administration (FDA||) [10].”
BackgroundBorrego, B., Lorenzo, G., Mota-Morales, J. D., Almanza-Reyes, H., Mateos, F., López-Gil, E., de la Losa, N., Burmistrov, V. A., Pestryakov, A. N., Brun, A., et al. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2016.01.021 · Cited by 129 · cited 1×
“On the other hand, in previous research, the in vitro antiviral effect of AgNPs has been demonstrated [23, 24].”
BackgroundSelf-citationYip, M., Leung, N., Li, P. H., Cheung, C. Y., Dutry, I., Li, D., Daëron, M., Bruzzone, R., Peiris, M. J. S., & Jaume, M. (2016) · PubMed · Cited by 123
Collagen-based silver nanoparticles for biological applications: synthesis and characterization
Cardoso, V. S., Quelemes, P. V., Amorin, A., Primo, F. L., Gobo, G. G., Tedesco, A. C., Mafud, A. C., Mascarenhas, Y. P., Corrêa, J. R., Kückelhaus, S. A. S., et al. (2014) · Journal of Nanobiotechnology · doi:10.1186/s12951-014-0036-6 · Cited by 102
SARS-coronavirus replicates in mononuclear cells of peripheral blood (PBMCs) from SARS patients
Li, L., Wo, J., Shao, J., Zhu, H., Wu, N., Li, M., Yao, H., Hu, M., & Dennin, R. H. (2003) · Journal of Clinical Virology · doi:10.1016/s1386-6532(03)00195-1 · Cited by 98 · cited 1×
“This leads to the fact that ADE-mediated secondary heterotypic infections caused by different coronavirus subtypes is the greatest risk factor [21, 22].”
BackgroundHo, H. J. A., Zhang, X., Huang, Z., Aung, A. H., Lim, W., & Chow, A. L. (2020) · Journal of Medical Internet Research · doi:10.2196/19437 · Cited by 74 · cited 1×
“International strategies focus on containment, diagnosis /monitoring, drug production and vaccines development against SARS-CoV-2 [7, 8].”
BackgroundOchoa-Meza, A. R., Sánchez, A. R. Á., Romo-Quiñonez, C. R., Barraza, A., Magallón‐Barajas, F. J., Chávez-Sánchez, A., García‐Ramos, J. C., Toledano‐Magaña, Y., Bogdanchikova, N., Pestryakov, A. N., et al. (2018) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2018.10.007 · Cited by 70 · cited 1×
“On the other hand, in previous research, the in vitro antiviral effect of AgNPs has been demonstrated [23, 24].”
BackgroundSelf-citationRepurposing 0.5% povidone iodine solution in otorhinolaryngology practice in Covid 19 pandemic
Khan, M. M., Parab, S. R., & Paranjape, M. (2020) · American Journal of Otolaryngology · doi:10.1016/j.amjoto.2020.102618 · Cited by 64 · cited 1×
“Contamination by nasal excretions can carry thousands of infectious particles, since a higher viral load has been demonstrated in the nasal cavity compared to the oral cavity [34].”
BackgroundHung, H.-Y., Tseng, Y.-H., Chao, H., Chiu, C., Hsu, W., Hsu, H., Wu, Y., Chou, T., Chen, C.-K., Lan, K.-L., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0236503 · Cited by 63
Duan, X., Sun, H., He, Y., Yang, J., Li, X., Taparia, K., & Zheng, B. (2020) · Journal of Occupational and Environmental Medicine · doi:10.1097/jom.0000000000002123 · Cited by 55 · cited 1×
“To reduce the morbidity and morbidity rate of healthcare personal, a variety of public health interventions have been implemented, such as the adaptation of areas with negative air pressure, isolation areas for patients with COVID-19, and the mandatory use of personal protective equipment (gloves, goggles, overalls an…”
BackgroundUskoković, V. (2020) · Nanomedicine · doi:10.2217/nnm-2020-0163 · Cited by 52
Could nasal irrigation and oral rinse reduce the risk for COVID-19 infection?
Casale, M., Rinaldi, V., Sabatino, L., Moffa, A., & Ciccozzi, M. (2020) · International Journal of Immunopathology and Pharmacology · doi:10.1177/2058738420941757 · Cited by 49
Wee, L. E., Hsieh, J. Y. C., Phua, G. C., Tan, Y., Conceicao, E. P., Wijaya, L., Tan, T. T., & Tan, B. H. (2020) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2020.207 · Cited by 48 · cited 1×
“International strategies focus on containment, diagnosis /monitoring, drug production and vaccines development against SARS-CoV-2 [7, 8].”
BackgroundSingh, V., Singh, S., Sharma, N., Singh, U., Singh, T., & Mangal, D. K. (2020) · Lung India · doi:10.4103/lungindia.lungindia_241_20 · Cited by 35
Yip, M., Cheung, C. Y., Li, P. H., Bruzzone, R., Peiris, M. J. S., & Jaume, M. (2011) · BMC Proceedings · doi:10.1186/1753-6561-5-s1-p80 · Cited by 34
Vrieling, M., Tuffs, S. W., Yebra, G., van Smoorenburg, M. Y., Alves, J., Pickering, A. C., Park, J. Y., Park, N., Heinrichs, D. E., Benedictus, L., et al. (2020) · mBio · doi:10.1128/mbio.02082-20 · Cited by 30
González, S. C., Mustafá, E. R., Rodríguez, S. S., Perelló, M., & Raingo, J. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00426 · Cited by 24
Personal Protective Equipment for COVID-19
Gopalakrishnan, M., Punitha, V., Prema, R., Niveathitha, S., & Saravanan, D. (2021) · Environmental footprints and eco-design of products and processes · doi:10.1007/978-981-16-3856-5_7 · Cited by 8
Can a Nasal/Oral/Ocular Spray Inactivate and Prevent SARS-CoV-2 infection? A hypothesis
Fuentes, E., & Santos-López, M. (2020) · International journal of odontostomatology · doi:10.4067/s0718-381x2020000400561 · Cited by 4
Metabolomics - a useful tool for prediction of protein production and processing?
Kronthaler, J., Schmidberger, T., & Heel, C. (2011) · BMC Proceedings · doi:10.1186/1753-6561-5-s8-p80 · Cited by 2
Cited by
Physical interventions to interrupt or reduce the spread of respiratory viruses
Jefferson, T., Dooley, L., Ferroni, E., Al-Ansary, L. A., van Driel, M. L., Bawazeer, G. A., Jones, M. A., Hoffmann, T. C., Clark, J., Beller, E. M., et al. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006207.pub6 · Cited by 291
Duman, H., Eker, F., Akdaşçi, E., Witkowska, A. M., Bechelany, M., & Karav, S. (2024) · Nanomaterials · doi:10.3390/nano14181527 · Cited by 247
“[109] Table 3.”
Silver Nanoparticles: Review of Antiviral Properties, Mechanism of Action and Applications
Luceri, A., Francese, R., Lembo, D., Ferraris, M., & Balagna, C. (2023) · Microorganisms · doi:10.3390/microorganisms11030629 · Cited by 223
“Prevention AgNPs (ArgovitTM) SARS-CoV-2 Prototype [37]”
BackgroundInfluentialRecent developments in the use of gold and silver nanoparticles in biomedicine
Pasparakis, G. (2022) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1817 · Cited by 141
Prophylaxis against covid-19: living systematic review and network meta-analysis
Bartoszko, J. J., Siemieniuk, R. A., Kum, E., Qasim, A., Zeraatkar, D., Martinez, J. P. D., Azab, M., Ibrahim, S., Izcovich, A., Soto, G. B., et al. (2021) · BMJ · doi:10.1136/bmj.n949 · Cited by 113
Metadata
- Authors
- Almanza-Reyes, H., Moreno, S., Plascencia-López, I., Alvarado-Vera, M., Patrón-Romero, L., Borrego, B., Reyes-Escamilla, A., Valencia-Manzo, D., Brun, A., Pestryakov, A., & Bogdanchikova, N.
- Affiliations
- Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (ES)
- Universidad Iberoamericana (MX)
- Tomsk Polytechnic University (RU)
- Universidad Nacional Autónoma de México (MX)
- Corresponding author
- Almanza-Reyes, Horacio
- Moreno, Sandra
- Alvarado-Vera, Martha
- Borrego, Belén
- Reyes-Escamilla, Alberto
- Valencia-Manzo, Daniel
- Brun, Alejandro
- Pestryakov, Alexey
- Bogdanchikova, Nina
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2021-08-19
- Volume
- 16
- Issue
- 8
- Pages
- e0256401
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC8375774
- OpenAlex
- W3193999063
- Cited by
- 102
- References
- 40
- Citations by year
- 2026: 1 · 2025: 18 · 2024: 20 · 2023: 27 · 2022: 30 · 2021: 6
- FWCI
- 6.30
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- medRxiv (acceptedVersion, cc-by-nd)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Tomsk Polytechnic University (Development Program "Priority 2030")
- Topics
- Physical Sciences › Materials Science › Materials Chemistry › Nanoparticles: synthesis and applications
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Infection Control and Ventilation
- Keywords
- silver nanoparticles, SARS-CoV-2, COVID-19 prevention, healthcare workers, mouthwash, infection control, nosocomial infections, antiviral activity
- MeSH terms
- COVID-19, SARS-CoV-2, Adolescent, Adult, Aged, Animals, Chlorocebus aethiops, Female, Health Personnel, Humans, Male, Mexico, Middle Aged, Mouthwashes, Silver, Vero Cells, Metal Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.